

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 8, 2002, 14:17:24 ; Search time 740.84 Seconds
(without alignments)
2013.587 Million cell updates/sec

Title: PCT-US01-47576-347
Perfect score: 1740
Sequence: 1 atgacacaaactgtatattcgg.....ccagtcacagcgaagtaa 1740

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 930621 seqs, 428662619 residues

Total number of hits satisfying chosen parameters: 1861242

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: N_Geneseq_1101.*
1: /SIDS2/gcgdata/geneseq/geneseq/NA1980.DAT.*
2: /SIDS2/gcgdata/geneseq/geneseq/NA1981.DAT.*
3: /SIDS2/gcgdata/geneseq/geneseq/NA1982.DAT.*
4: /SIDS2/gcgdata/geneseq/geneseq/NA1983.DAT.*
5: /SIDS2/gcgdata/geneseq/geneseq/NA1984.DAT.*
6: /SIDS2/gcgdata/geneseq/geneseq/NA1985.DAT.*
7: /SIDS2/gcgdata/geneseq/geneseq/NA1986.DAT.*
8: /SIDS2/gcgdata/geneseq/geneseq/NA1987.DAT.*
9: /SIDS2/gcgdata/geneseq/geneseq/NA1988.DAT.*
10: /SIDS2/gcgdata/geneseq/geneseq/NA1989.DAT.*
11: /SIDS2/gcgdata/geneseq/geneseq/NA1990.DAT.*
12: /SIDS2/gcgdata/geneseq/geneseq/NA1991.DAT.*
13: /SIDS2/gcgdata/geneseq/geneseq/NA1992.DAT.*
14: /SIDS2/gcgdata/geneseq/geneseq/NA1993.DAT.*
15: /SIDS2/gcgdata/geneseq/geneseq/NA1994.DAT.*
16: /SIDS2/gcgdata/geneseq/geneseq/NA1995.DAT.*
17: /SIDS2/gcgdata/geneseq/geneseq/NA1996.DAT.*
18: /SIDS2/gcgdata/geneseq/geneseq/NA1997.DAT.*
19: /SIDS2/gcgdata/geneseq/geneseq/NA1998.DAT.*
20: /SIDS2/gcgdata/geneseq/geneseq/NA1999.DAT.*
21: /SIDS2/gcgdata/geneseq/geneseq/NA2000.DAT.*
22: /SIDS2/gcgdata/geneseq/geneseq/NA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	1740	100.0	1740	21 AAC66035	Human lung cancer-
2	1736.8	99.8	1740	21 AAC66035	DNA encoding cancer-
3	1736.8	99.8	1740	21 AAC66035	Human lung cancer-
4	803.6	46.2	2224	20 AA210617	CDNA encoding a mu
5	712	40.9	3412	21 AA236152	DNA encoding cancer
6	697.2	40.1	3283	21 AA236154	An alternative for
7	674.2	38.7	1946	21 AA236153	DNA encoding cancer
8	582.2	33.5	1708	21 AA236151	DNA encoding cancer
9	381.4	21.9	444	21 AAC17226	Human secreted pro
10	280.4	16.1	282	22 AA156378	Probe #25064 used
11	280.4	16.1	588	22 AA143398	Probe #12084 used

12	263.2	15.1	710	21 AAA02565	Human colon cancer
13	163.2	9.4	364	21 AAC03267	Human secreted pro
14	137.4	7.9	500	22 AA142184	Probe #10874 used
15	136	7.8	136	22 AA15289	Probe #23955 used
16	121.8	7.0	424	21 AAH31011	Human colon cancer
17	99.4	5.7	300	21 AAA01526	Human colon cancer
18	80.4	4.6	936	22 AA58252	Oligonucleotide n1
19	80.4	4.6	936	22 AA58254	Oligonucleotide n1
20	80.4	4.6	936	22 AA58257	Oligonucleotide n1
21	80.4	4.6	936	22 AA58259	Oligonucleotide n1
22	80.4	4.6	936	22 AA58262	Oligonucleotide n1
23	80.4	4.6	936	22 AA58265	Oligonucleotide n1
24	75.8	4.4	936	22 AA58267	Oligonucleotide n1
25	75.8	4.4	936	22 AA58269	Oligonucleotide n1
26	75.8	4.4	936	22 AA58272	Oligonucleotide n1
27	75.8	4.4	936	22 AA58275	Oligonucleotide n1
28	75.8	4.4	936	22 AA58278	Oligonucleotide n1
29	75.8	4.4	936	22 AA58281	Oligonucleotide n1
30	44.6	2.6	598	22 AA58284	Oligonucleotide n1
31	42.2	2.4	244	22 AA58287	Oligonucleotide n1
32	42.2	2.4	244	22 AA58290	Oligonucleotide n1
33	41.6	2.4	4590	22 AA58293	Oligonucleotide n1
34	41.2	2.4	2396	21 AAC46033	Oligonucleotide n1
35	41.2	2.4	2401	21 AAC46042	Oligonucleotide n1
36	40.6	2.3	773	22 AAH03905	Oligonucleotide n1
37	40.6	2.3	2773	22 AAH17152	Oligonucleotide n1
38	39	2.2	2767	21 AA58296	Oligonucleotide n1
39	38.8	2.2	580073	18 AA58299	Oligonucleotide n1
40	38.4	2.2	3738	21 AA58302	Oligonucleotide n1
41	38.2	2.2	2541	21 AA58305	Oligonucleotide n1
42	37.8	2.2	1653	21 AA58308	Oligonucleotide n1
43	37.8	2.2	2917	20 AA58311	Oligonucleotide n1
44	37.8	2.2	2917	20 AA58314	Oligonucleotide n1
45	37.8	2.2	2917	22 AA58317	Oligonucleotide n1

ALIGNMENTS

RESULT 1	
ID AAC66035 standard; CDNA: 1740 BP.	
AC AAC66035;	
XX 21-FEB-2001 (first entry)	
DT XX	
DE Human lung cancer-associated CDNA antigen L5235.	
XX	
KW Lung cancer; therapy; treatment; human; tumor; immunogenic; cytostatic;	
KW vaccine; detection; ss.	
XX	
OS Homo sapiens.	
XX	
PN WC2000061612-A2.	
XX	
PD 19-OCT-2000.	
XX	
PF 03-APR-2000; 2000MO-US08896.	
XX	
PR 02-APR-1999; 99US-0285479.	
PR 17-DEC-1999; 99US-046396.	
PR 30-DEC-1999; 99US-0476496.	
PR 10-JUN-2000; 2000US-0480884.	
PR 22-FEB-2000; 2000US-0510376.	
XX	
PA (COR-) CORIXA CORP.	
XX	
PI Wang T, Fan L,	
XX	
DR WPI; 2000-628399/60.	
DR P-PSDB; AA11365.	
XX	

AC AA236150;
XX 11-FEB-2000 (first entry)
XX DNA encoding cancer associated antigen KOC-1.
XX
XX Cancer associated antigen: KOC-1; cancer: vaccine; CT7; 8S.
XX Homo sapiens.
XX MO9954738-A1.
XX 28-OCT-1999.
XX 16-MAR-1999; 99MO-US05766.
XX 17-APR-1998; 98US-0061709.
XX (LUDWIG) LUDWIG INST CANCER RES.
XX Chen Y, Gure A, Tsang S, Stockert E, Jager E, Knuth A, Old LJ;
XX WPI: 2000-013284/01.
XX
XX Nucleotides representing cancer-associated genes, used to develop
XX products for the diagnosis, monitoring and treatment of cancers
XX
XX Claim 88: Page 39-40; 44pp: English.
XX
XX The present sequence represents a cancer associated antigen gene
XX designated KOC-1. The specification also describes a cancer associated
XX antigen designated CT7. The CT7 polynucleotide was isolated from
XX SK-MEL-37 melanoma cells. The polypeptide has some homology with
XX MAC-10, limited to about 210 carboxy terminal amino acids. The amino
XX terminal of the protein has a repetitive pattern, with repeats rich in
XX serine, proline, glutamine and leucine, and an almost invariable core of
XX the peptide given in AA43877. The CT7 polypeptide can be processed to
XX peptides which provoke lysis by cytolytic T cells. The polynucleotides
XX and polypeptides can be used for treating a cancerous condition and
XX screening for or diagnosing cancerous conditions. The cancer associated
XX antigen can be used as an immunogenic or vaccine composition with an
XX adjuvant, e.g. a cytokine, a saponin, or granulocyte macrophage-colony
XX stimulating factor (GM-CSF).
XX
XX Sequence 4159 BP; 1281 A; 830 C; 851 G; 1181 T; 16 other;
XX
XX Query Match 99.8%; Score 1736.8; DB 21; Length 4159;
XX Best Local Similarity 99.8%; Pred. No. 0;
XX Matches 1738; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 551 ctatgccagatgagatggtgagagctgtgagcagtgagacacatgactcgaaactgca 610
Oy 361 gtgttaaatgtaacattccatccagtaaggacaaagctgaaacacatgaaactgaat 420
Db 611 gtgttaaatgtaacattccatccagtaaggacaaagctgaaacacatgaaactgaat 670
Oy 421 ggaattcagttagaagaatttcacacctgaaagtaagcctatactccatgataagacgagcc 480
Db 671 ggaattcagttagaagaatttcacacctgaaagtaagcctatactccatgataagacgagcc 730
Oy 481 cagcaaaaaccccttgacagagcccgagagctgcggggggttgaggagggggtcccca 540
Db 731 cagcaaaaaccccttgacagagcccgagagctgcggggggttgaggagggggtcccca 790
Oy 541 aggcaggggtgtctccagatcgtatcccaagcagaacacatgatttgcctcgcgcctg 600
Db 791 aggcaggggtgtctccagatcgtatcccaagcagaacacatgatttgcctcgcgcctg 850
Oy 601 ctggttccaccccaattgttgagagccatctaggaagaagatgcccacatcggaaac 660
Db 851 ctggttccaccccaattgttgagagccatctaggaagaagatgcccacatcggaaac 910
Oy 661 atcaccaaacagaccacagctctaaatcgtatccacccgttaagaagaatgctgggtgct 720
Db 911 atcaccaaacagaccacagctctaaatcgtatccacccgttaagaagaatgctgggtgct 970
Oy 721 gaggagtgatgatact 780
Db 971 gaggagtgatgatact 1030
Oy 781 ctggagattatgataaggaagctcaagatataaaatcacaagaagaagatcccttgaag 840
Db 1031 ctggagattatgataaggaagctcaagatataaaatcacaagaagaagatcccttgaag 900
Oy 841 atttgatcattatgaactctgttgagagctctatctgttgaagaagaagaagatcttaa 960
Db 1091 atttgatcattatgaactctgttgagagctctatctgttgaagaagaagaagatcttaa 1150
Oy 901 aaaaattgagcaagacacagacactaaatcacaagatctccatctggaagatctgagctg 960
Db 1151 aaaaattgagcaagacacagacactaaatcacaagatctccatctggaagatctgagctg 1210
Oy 961 tatatcccaaaagcagct 1020
Db 1211 tatatcccaaaagcagct 1270
Oy 1021 gaggagatcagaaagaatcagagagctctgaagaagaagaagaagaagaagaagaaga 1080
Db 1271 gaggagatcagaaagaatcagagagctctgaagaagaagaagaagaagaagaagaaga 1330
Oy 1081 caagacacatttaattccttgatataatctgaaagcctctggtctgtctccacacaccca 1140
Db 1331 caagacacatttaattccttgatataatctgaaagcctctggtctgtctccacacaccca 1390
Oy 1141 gggatgccaactccac 1200
Db 1391 gggatgccaactccac 1450
Oy 1201 gaggcaatcagaagaagagctgtcatctgttatacccaatcagatcagtgagcactc 1260
Db 1451 gaggcaatcagaagaagagctgtcatctgttatacccaatcagatcagtgagcactc 1510
Oy 1261 atcggaagcagggcagagacatcaagcagctctcgccttgagagcttcaatgaag 1320
Db 1511 atcggaagcagggcagagacatcaagcagctctcgccttgagagcttcaatgaag 1570
Oy 1321 atgtctccagcaggaagcagcagatctaaagtggagtggtgttctacactgagacacca 1380
Db 1571 atgtctccagcaggaagcagcagatctaaagtggagtggtgttctacactgagacacca 1630
Oy 1381 gaggctcagttcagaagctcagaagaagaattatggaagaagaagaagaagaagaactgtc 1440
Db 1631 gaggctcagttcagaagctcagaagaagaattatggaagaagaagaagaagaagaactgtc 1690

OY 1441 agctcaaaagagagtgtaaaccttgaaactcatatcatatcagagtgccatcttgctgctgc 1500
 DB 1691 agctcaaaagagagtgtaaaccttgaaactcatatcatatcagagtgccatcttgctgctgc 1750
 OY 1501 agagtgatctggaag 1550
 DB 1751 agagtgatctggaag 1810
 OY 1561 gttgtgtccctcgtgagacag 1620
 DB 1811 gttgtgtccctcgtgagacag 1870
 OY 1621 gttgtgtccctcgtgagacag 1680
 DB 1871 gttgtgtccctcgtgagacag 1930
 OY 1681 agagtgatctggaag 1740
 DB 1931 agagtgatctggaag 1990

RESULT 3

AAC65900

ID AAC65900 standard; cDNA; 4181 BP.

AC AAC65900:

DT 21-FEB-2001 (first entry)

DE Human lung cancer-associated cDNA L5235.

KW Lung cancer; therapy; treatment; human; tumor; immunogenic; cytostatic;
 vaccine; detection; ss.

OS Homo sapiens.

PN M0200061612-A2.

PD 19-OCT-2000.

PF 03-APR-2000; 2000MO-US08896.

PR 02-APR-1999; 99US-0285479.

PR 17-DEC-1999; 98US-0466396.

PR 30-DEC-1999; 98US-0476486.

PR 10-JAN-2000; 2000US-0480894.

PR 22-FEB-2000; 2000US-0510376.

PA (COR1-) COR1XA CORP.

P1 Wang T, Fan L.

DR WPI: 2000-628399/60.

PT P-PSDB: AAB11328.

PT Isolated polypeptide comprising an immunogenic portion of a lung tumor
 protein, is used for detecting and monitoring progression of lung cancer
 in a patient.

XX Claim 1a: Page 184-186; 261pp; English.

CC This invention describes a novel isolated polypeptide (I) which
 CC comprising an immunogenic portion of a lung tumor protein or variant (P2)
 CC which have cytostatic activity. The polypeptides and polynucleotides are
 CC used in compositions and vaccines to inhibit the development of cancer,
 CC especially lung cancer. In a patient. Methods described in the invention
 CC can be used to monitor the progression of a cancer by carrying out the
 CC detection at subsequent time points and comparing the results from the
 CC different time points. CD4+ and/or CD8+ T-cells isolated from a patient
 CC are treated with P2, polynucleotides encoding P2 or antigen presenting
 CC cells expressing P2 and then administered to the patient to inhibit
 CC development of cancer.

XX
 SO Sequence 4181 BP; 1303 A; 830 C; 851 G; 1181 T; 16 other:

Query Match 99.8%; Score 1736.8; DB 21; Length 4181;
 Best Local Similarity 99.9%; P-DB: 0;
 Matches 1736; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1 atgacaacactgtatatacggaaacactcagcagagacgcgcgcctcggacactgaaagt 60
 DB 251 atgacaacactgtatatacggaaacactcagcagagacgcgcgcctcggacactgaaagt 110
 OY 61 atctcaaaag 120
 DB 311 atctcaaaag 170
 OY 121 ttcgtgagactgacccgagacgagagagagagagagagagagagagagagagagagagag 180
 DB 371 ttcgtgagactgacccgagacgagagagagagagagagagagagagagagagagagagag 430
 OY 181 atagagactgacgag 240
 DB 431 atagagactgacgag 490
 OY 241 cggagaaacttcagatacgaataatcccgccatattacagtgagagagagagagagagag 300
 DB 491 cggagaaacttcagatacgaataatcccgccatattacagtgagagagagagagagagag 550
 OY 301 ctgagtcagatag 360
 DB 551 ctgagtcagatag 610
 OY 361 gttgtgaaatgtgaacactcattccagtagaagagagagagagagagagagagagagagag 420
 DB 611 gttgtgaaatgtgaacactcattccagtagaagagagagagagagagagagagagagagag 670
 OY 421 ggaattcagatgag 480
 DB 671 ggaattcagatgag 730
 OY 481 cagcaaaacccctcgcag 540
 DB 731 cagcaaaacccctcgcag 790
 OY 541 aggcag 600
 DB 791 aggcag 850
 OY 601 ctggttcccaaccatattgttggag 660
 DB 851 ctggttcccaaccatattgttggag 910
 OY 661 atcaccacaaag 720
 DB 911 atcaccacaaag 970
 OY 721 gggag 780
 DB 971 gggag 1040
 OY 781 ctggagatattgcaataag 840
 DB 1031 ctggagatattgcaataag 1090
 OY 841 atttagtcaataaacttctgttgag 900
 DB 1091 atttagtcaataaacttctgttgag 1150
 OY 901 aaattggag 960
 DB 1151 aaattggag 1210
 OY 961 tataatccagaaacgacattatag 1020

